.svg)
In cancer care, no two tumors are exactly alike, and increasingly, treatment is not one-size-fits-all. A new clinical study, published in Nature Medicine, known as the ROME trial, offers some of the strongest evidence yet that tailoring cancer therapies to a person’s unique tumor genetics can improve outcomes, even when traditional options have ceased to be effective.
What the ROME Trial Tested
The ROME trial, short for Randomized study Of Molecularly guided thErapy, was a large nationwide study across 40 oncology centers in Italy. It enrolled nearly 1,800 people with advanced solid tumors, meaning cancers that had already spread or returned after up to two previous treatments.
Each patient’s tumor was analyzed using comprehensive genomic profiling, which looks for genetic changes that may be driving cancer growth. These results were reviewed by a molecular tumor board, a team of oncologists, geneticists, and scientists, who decided whether a targeted treatment was available for each patient.
Four hundred patients were ultimately assigned to one of two groups:
- Tailored treatment (TT), which matched therapy to the tumor’s genetic alterations
- Standard of care (SoC), which used the typical treatment for that cancer type
Key Findings
The results were clear: people who received genomically matched therapies fared better overall.
- Response rate: 17.5% of patients in the tailored treatment group experienced tumor shrinkage or disappearance, compared with 10% in the standard care group.
- Progression-free survival: Patients on tailored therapies lived an average of 3.5 months without their disease worsening, compared with 2.8 months for standard treatments. The likelihood of remaining progression-free at one year was 22% versus 8%, respectively.
- Treatment tolerance: Serious side effects were similar between the two groups (40% for TT compared with 52% for SoC), showing that more personalized therapies did not increase toxicity.
While overall survival times were similar, more than half of the patients receiving standard treatment later crossed over to a tailored therapy once their disease progressed. This ethical decision likely narrowed the survival difference between the two groups.
Why This Matters
For years, doctors have known that some cancers respond better when treated based on their molecular fingerprint rather than their location in the body. Drugs that target specific mutations such as BRAF, HER2, or RET can be effective across multiple cancer types. However, very few randomized clinical trials have directly compared precision-based treatments to traditional options.
The ROME trial changes that. It demonstrates that using genomic testing to guide treatment decisions can provide real clinical benefits for people with difficult-to-treat cancers, regardless of where their cancer began.
The Role of Molecular Tumor Boards
One of the most powerful aspects of the study was its reliance on a molecular tumor board. This multidisciplinary group assisted doctors in interpreting complex genetic data and matching patients to the most promising therapies. The ROME trial demonstrated that molecular tumor boards are not only beneficial in theory, but can also directly improve patient outcomes.
What Comes Next
The findings suggest that precision oncology, which utilizes molecular information to inform care, should play a more significant role in routine cancer treatment. They also highlight the importance of identifying patients for genomic testing earlier, before their health declines or treatment options become limited.
At Kadance, this proactive, genomically informed approach represents the future of healthcare. By combining advanced testing with expert guidance, programs like ours enable patients and clinicians to make informed decisions.
The ROME trial provides compelling evidence that when care is truly personalized, patients can benefit in both meaningful and measurable ways.
Reference:
Marchetti P., et al. (2025). Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.Nature Medicine. https://doi.org/10.1038/s41591-025-03918-x